America, Hershey, PA Australia, Melbourne, VIC Europe, Munich
|
|
|
- Ashley Garrett
- 5 years ago
- Views:
Transcription
1 America, Hershey, PA Australia, Melbourne, VIC Europe, Munich Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma no yes Brain A172 Glioblastoma no yes C6 Rat glial cell; gliaoma ; fibroblast no no DAOY desmoplastic cerebellar medulloblastoma yes yes GI-LI-N Neuroblastoma no yes IMR-32 human Neuroblastoma no yes LAN-5 Neuroblastoma no yes SNB-19 glioblastoma no yes U87MG glioblastoma; astrocytoma yes yes yes +/- luc Breast T1 Mouse breast carcinoma yes yes yes, also as metastasis model +/- luc, lung liver mets 2 BT-7 breast carcinoma yes yes yes Estrogen dependent, hormone pellets HER2 pos 2- EMT6 Mouse breast carcinoma yes no yes, also as metastasis model lung mets 2 HC 11 Mouse not tumorigenic yes HC 11-NeuT Mouse yes yes HCC195 breast carcinoma yes no yes slow growing, C.B-17 SCID HER2 pos 6 Hs 578Bst myoepithel, fibroblast not tumorigenic yes Hs578T myoepithel, fibroblast yes yes Estrogen dependent, hormone MCF-7 breast carcinoma yes yes yes pellets MCF-10A breast carcinoma no yes HER2 pos MDA -MB-231 breast adenocarcinoma, Pleural yes yes yes, also metastasis model +/- luc for ortho 2 for subq for very attractive prices. Please contact us for details! Page 1 of 5 Last Updated: Mar 1, 2016
2 MDA-MB-361 breast carcinoma yes no HER2 pos MDA-MB-53 breast carcinoma yes yes HER2 pos MDA-MB-68 breast adenocarcinoma yes yes yes, also as metastasis model in slow growing 7 MMT Mouse breast carcinoma no yes SK-BR-3 breast carcinoma no yes HER2 pos T7D breast carcinoma not tumorigenic no Colon C170 adenocarcinoma, colorectal yes Colo-201 carcinoma, colorectal yes yes yes Colo-205 carcinoma, colorectal yes yes yes induction of cachexia 3- CT-26 Mouse carcinoma, colorectal yes no yes DLD-1 carcinoma, colorectal no yes 2 HCT-15 carcinoma, colorectal yes yes 2 HCT 116 carcinoma, colorectal yes yes yes 2- HT-29 adenocarcinoma, colorectal yes yes yes 2 Km12L carcinoma, colorectal no no LoVo carcinoma, colorectal yes no s.c. sensitive to 5FU 3- MC-38 Mouse adenocarinoma yes yes no C57BL/6 SW80 carcinoma, colorectal yes no SW620 carcinoma, colorectal yes no resistant WiDr carcinoma, colorectal yes no 2 Connective HT-1080 fibrosarcoma yes yes L-929 Mouse subcutaneous connective tissue; areolar and adipose not tumorigenic yes Sarcoma 180 Mouse sarcoma no yes Head & Neck SCC-15 squamous cell carcinoma no yes Kidney not tumorigenic, very slow growing 786-O renal cell adenocarcinoma yes yes not tested slow growing 3-5 ACHN renal cell adenocarcinoma yes yes not tested slow growing 3-5 Leukemia/Lymphoma - Bone Marrow RS()11 Acute lymphoblastic leukemia no yes SUP-B15 Acute lymphoblastic leukemia, B lymphoblast K-562 chronic myelogenous leukemia (CML) bone marrow yes yes 3- L-50 Hodgkin lymphoma no yes NCI-H929 Plasmacytoma, multiple myeloma (MM), B lymphocyte yes no in bone marrow of the tibia for very attractive prices. Please contact us for details! Page 2 of 5 Last Updated: Mar 1, 2016
3 Leukemia/Lymphoma - Peripheral Blood CCRF-CEM T lymphoblast, acute lymphoblastic leukemia no yes CEM/C1 T lymphoblast, acute lymphoblastic leukemia yes yes Daudi B lymphoblast, Burkitt's lymphoma (NHL) yes yes yes iv injection in SCID mice HD-MY-Z Hodgkin lymphoma no HL-60 Acute promyelocytic leukemia, promyeloblast yes yes from fragments KASUMI-1 Acute myeloblastic leukemia, myeloblast yes no L-1236 Hodgkin lymphoma no yes LP-1 Plasmacytoma, multiple myeloma yes no in bone marrow of the tibia MOLM-13 Acute myeloid leukemia no yes MOLT- Acute lymphoblastic leukemia, T lymphoblast no yes used in screening MUTZ-2 acute myeloid leukemia no yes used in screening MV()11 biphenotypic B myelomonocytic leukemia, macrophage yes yes yes i.v. injection in NOD SCID OCI-AML 2 Acute myeloid leukemia no yes used in screening PEER T cell acute lymphoblastic leukemia (T-ALL) no yes used in screening Raji Burkitt's lymphoma, B lymphocyte yes yes yes Ramos Burkitt s lymphoma, B lymphocyte yes no yes RPMI 8226 Plasmacytoma, multiple myeloma, B lymphocyte yes yes SKM-1 Acute myeloid leukemia no yes U937 Histiocytic lymphoma no yes Liver Hep 3B2.1-7 hepatocellular carcinoma yes yes yes HEPA 1-6 Mouse yes yes iv injection in SCID, also available as luc clone subcutaneous and orthotopic, >90% take rate HUH-7 carcinoma yes yes yes variable and fast growing, also available as luc2 3 PLC/PRF/5 hepatoma yes SK-HEP-1 adenocarcinoma yes yes yes SNU-182 hepatocellular carcinoma yes Lung A59 NSCLC yes yes 2 Calu-3 adenocarcinoma (Pleural effusion) yes no 3- Calu-6 H69AR HCC827 epithelial HOP-92 NSCLC, pleural effusion no yes 3- LL/2 Mouse Lewis Lung (C57BL6) yes no yes with LL-2 luc for very attractive prices. Please contact us for details! Page 3 of 5 Last Updated: Mar 1, 2016
4 NCI-H69 SCLC, Small Cell Carcinoma yes yes from fragments 3- NCI-H82 NSCLC yes no 2- NCI-H16 NSCLC yes yes NCI-H209 SCLC, Small Cell Carcinoma yes yes high variability 3 NCI-H226 NSCLC yes yes NCI-H60 NSCLC, pleural effusion yes yes also with NCI-H60 luc 2 2- NCI-H520 NSCLC, Squamous cell carcinoma yes yes 2-3 NCI-H596 NSCLC, adenosquamous carcinoma yes yes from fragments -6 NCI-H1975 epithelial NCI-H1975 WI-38 normal fibroblast not tumorigenic yes Ovary A2780 ovary, adenocarcinoma yes 2-3 ADDP ovary, adenocarcinoma no no NCI ADR-res ovary, adenocarcinoma no yes NIH;OVCAR-3 ovary, adenocarcinoma yes yes SCID mice 5 NIH;OVCAR- ovary, adenocarcinoma no no NIH;OVCAR-5 ovary, adenocarcinoma no no SK-OV-3 adenocarcinoma, ovary, Malignant Ascites yes yes not tested SCID mice also available as SKOV3-luc-D3 Pancreas AsPC-1 adenocarcinoma no yes BxPC-3 adenocarcinoma yes yes 3-5 Capan-1 from liver mets no yes HupT L3.6pl carcinoma yes no metastasis in LN, pancectomy in preparation 2- MIA PaCa-2 carcinoma yes yes yes in Athymic Foxn1 nude 2- PANC-1 epithelioid carcinoma yes yes SCID mice 3-6 Pan02 Mouse carcinoma yes no C57Bl6 5 Prostate DU 15 prostate carcinoma yes yes slow growth rate LN-CaP prostate carcinoma yes yes Androgen depended -6 PC3 prostate adenocarcinoma yes yes inoculation into tibia tested (bone lysis model) also as 2-3 PC3 -luc prostate model PC3-M prostate adenocarcinoma yes yes metastasis, induction of cachexia 2-3 Skin A375 malignant melanoma yes yes 2-3 A31 B16-F0 Mouse melanoma yes in progress Yes, C57BL/6 (intradermal) Pancreas for very attractive prices. Please contact us for details! Page of 5 Last Updated: Mar 1, 2016
5 B16-F10 Mouse melanoma yes yes Yes, C57BL/6 (intradermal) 2 C32 melanoma yes no s.c. 2 C8161 malignant melanoma yes no Yes, Athymic nude (intradermal) metastatic clone (lung) 3 CHL-1 melanoma yes no fast growing 2 G361 malignant melanoma yes yes HT 1 malignant melanoma yes Malme-3 malignant melanoma no yes Malme-3M malignant melanoma no yes lung and liver metastasis, induction of cachexia Orthotopic (intradermal) MDA-MB-35S melanoma not tumorigenic no not tested low take rate 3 SK-MEL-2 malignant melanoma no yes SK-MEL-5 malignant melanoma no yes SK-MEL-28 malignant melanoma no yes WM-266- melanoma, from metastatic site yes Stomach MKN-5 human, stomach, adenocarcinoma yes yes NCI-N87 gastric carcinoma no yes Testis F9 Mouse no yes Thyroid BHT-101 squamous cell carcinoma no yes 1-2 SW579 squamous cell carcinoma no yes Uterus MES-SA Uterine Sarcoma no yes MES-SA/Dx5 Uterine Sarcoma no yes Vulva SK-LMS-1 leiomysarcoma no no Other Hela cervical carcinoma no yes for very attractive prices. Please contact us for details! Page 5 of 5 Last Updated: Mar 1, 2016
Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2
![Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2](/thumbs/88/116309357.jpg "Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2")
America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Tissue Bladder Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-
Human cell line list Production of Exosome Standards - Cell Lysates
Human cell line list 2016 - Production of Exosome Standards - Cell Lysates 380 peripheral blood leukemia, pre-b cell 1301 blood leukemia, acute lymphoblastic, T cell 5637 bladder carcinoma 8305C thyroid
HansaBioMed Catalog 2014 for Exosome Research. X. Human Cell Lines...
HansaBioMed Catalog 2014 for Exosome Research X..... HansaBioMed Catalog 2014 HUMAN CELL LINES 380 leukemia, pre-b cell 1301 leukemia, acute lymphoblastic, T cell suspension, morphology round, small cells
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
Supplementary Materials for
advances.sciencemag.org/cgi/content/full/2/12/e1601756/dc1 Supplementary Materials for Syrosingopine sensitizes cancer cells to killing by metformin Don Benjamin, Marco Colombi, Sravanth K. Hindupur, Charles
Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors
Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors Philippe Slos 2 nd Annual ICI March 15-17, 2016 Boston Introduction
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center Overview of Anticancer Drug Development Discovery Non-clinical development Clinical Trial Target Identification
Sample validation data
Bioware and Bioware Ultra oncology cell lines Sample validation data Animal models and cell injection number A549-luc-C8 (Cat. No. 119266) Model Subcutaneous Intravenous Male nu/nu Male nu/nu (Charles
MOLECULAR PHARMACOLOGY SUPPLEMENT
MOLECULAR PHARMACOLOGY SUPPLEMENT Therapeutic targeting of a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate
Supplementary Figure 1: Normal vs. Tumor expression of PIM kinases mrna across 17 tissue types
Supplementary Figure 1: Normal vs. Tumor expression of PIM kinases mrna across 17 tissue types Supplementary Figure 1 Legend: PIM1, PIM2 and PIM3 mrna expression Expression levels in cancer tissues derived
CLIC Sargent Eligibility Criteria
1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd
Macmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Supplemental Methods LC-MS Assay for NAD Concentration
Supplemental Methods LC-MS Assay for NAD Concentration The concentration of NAD in cells was determined by a non-validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay using 13 C 5 -NAD
LavaCell. Fluorescent Cell Stain. (version A) Catalog No
LavaCell Fluorescent Cell Stain (version A) Catalog No. 15004 Active Motif North America 1914 Palomar Oaks Way, Suite 150 Carlsbad, California 92008, USA Toll free: 877 222 9543 Telephone: 760 431 1263
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
incidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
Antitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models
Antitumor Activity of CUDC-5, a Novel Oral HSP Inhibitor, in Solid and Hematological Tumor Xenograft Models Rudi Bao, MD/PhD April 1, 2 AACR 1th Annual Meeting 2 Experimental and Molecular Therapeutics
Broad Spectrum, Targeted Approaches To Cancer Treatment
SELECTIVELY KILLING CANCER CELLS Broad Spectrum, Targeted Approaches To Cancer Treatment Safe Harbor The presentation made during this meeting and other statements by ArQule may contain forward-looking
ACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
Oncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
Figure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h
Figure S1 Time-dependent down-modulation of HER3 by EZN-392 HE ER3 mrna A, %Contr rol 12 No Treatment EZN-392, 2 μm 1 8 6 4 2 2 8 24 Time, h Figure S2. Specific target down-modulation by HER3 (EZN-392)
Cancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
Charles River Immunodeficient Models Xenograft Data Catalog
Charles River Immunodeficient Models Xenograft Data Catalog Fox Chase SCID Congenic (C.B-17 SCID) Mouse Xenograft Data askcharlesriver@crl.com www.criver.com 214, Charles River Laboratories International,
NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)
Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed
Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly
PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS
PATIENT-DERIVED ORTHOTOPIC ENOGRAFTS THE ONLY CLINICALLY-RELEVANT MOUSE TUMOR MODEL CRYOPRESERVATION OF PDO TUMORS DRUG DISCOVERY FOR PHARMA, BIOTECH & ACADEMIA FLUORESCENCE IMAGING & CELL LINES PRE-CLINICAL
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays Excellent precision Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Markers Parameter Clinical Interest Product Technology
The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.
Acknowledgment The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light. Special appreciation goes to: Prof Amal Samy
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
Cancer in the organ donor
Cancer in the organ donor Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta>on CHU Liège, University of Liege, Belgium olivier.detry@transplanta>on.be Conflicts of Interest Conflicts of Interest
Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
Epidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
Supplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with
Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with or without alterations in PTEN or PIK3CA. Cell Line Tissue Type Ipatasertib IC 50 (μmol/l) a
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
Cancer model Liver metastasis I
Cancer model Liver metastasis I H. Suemizu, M. Monnai, Y. Ohnishi, M. Ito, N. Tamaoki, and M. Nakamura. 2007. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma
Purified Exosomes and Microvesicles
1 Summary Section 1 Introduction 4 Lyophilized Exosome Standards 5 Lyophilized Microvesicles 10 Exosomes and Microvesicles available on request 14 1 Available products Lyophilized Exosomes from cell conditioned
Heart Failure Transitions of Care SJMH - Ann Arbor
Heart Failure Transitions of Care SJMH - Ann Arbor March 4, 2013 Cecelia Montoye, RN, MSN Reducing 30 Day Heart Failure Readmissions: SJMH Ann Arbor See you in 7 Measures Process Measure #4: Identify and
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center
Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center Animal Models for Translational Research How to apply preclinical translational research New trial concept of
Burden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
Colorectal Cancer Screening
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
Cancer A Superficial Introduction
Cancer A Superficial Introduction Gabor Fichtinger, Queen s University Cancer some definitions Medical term: malignant neoplasm Class of diseases in which a group of cells display: uncontrolled growth
Maria Halasz CEO
Australian biotechnology company listed on the ASX (CDY.AX) Midkine company owns novel therapeutic and diagnostic target Extensive scientific validation including 550+ publications Multiple revenue source
Radiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
Epidemiology of SV40-Associated Tumors
Epidemiology of SV40-Associated Tumors Susan G. Fisher, Ph.D. Chief, Division of Epidemiology Community & Preventive Medicine University of Rochester Background Mass polio immunization program in U.S.
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
Disease Source Species Name ATCC No. ATCC has approximately 1,100 tumor cell lines from a variety of species. Disease Source Species Name ATCC No.
ATCC has approximately 1,100 tumor cell lines from a variety of species. This list includes tumor cells from primary sites or from sources in which the primary/metastatic status is unknown. They are listed
Supplementary information table of content
Supplementary information table of content 13 supplementary tables Supplementary Table S1. List of the 4356 genes and corresponding antibodies used in the study. Separate excel file available. Supplementary
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER
Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER Table 1.1 gives the total number of cancers diagnosed at five different hospital based cancer registries (HBCRs), over the period of two years from 1st January
Genetic Alteration Panels
TM Genetic Alteration Panels GENETIC ALTERATION PANELS Table of Contents AKT Genetic Alteration Panel (ATCC No. TCP-1029 )...1 BRAF Genetic Alteration Panel (ATCC No. TCP-1032 )...5 EGFR Genetic Alteration
The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines
Supplementary information Supplementary Figure -9 Supplementary Table -4 The mir-99a/brm/egr axis is a determinant of anchorage-independent growth in epithelial tumor cell lines Kazuyoshi Kobayashi, Kouhei
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin Hodgkin s s Lymphoma Targeted Cancer Therapies William Westlin, Ph.D. Vice President, Preclinical Research Discovery of Fumagillin
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
Supplementary Material
Supplementary Material Original article in Gastric Cancer A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor
Growth Surface References
Growth Surface References Which options do I have for the cultivation of my cells? TC Tested Sterile/ DNA-/ DNase-/ RNase-/ Pyrogen-free/ non-cytotoxic Come Grow with us 2 Are you planning to add a new
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling
SUPPLEMENTARY INFORMATION Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling Jian-Guo Ren 1, Pankaj Seth 1, Clary B. Clish 2, Pawel K. Lorkiewicz
Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date
MP 8.01.03 Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
Nuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
Cancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer
Cancer in Ontario 1 in 2 Ontarians will develop cancer in their lifetime 1 in 4 Ontarians will die from cancer 14 ONTARIO CANCER STATISTICS 2016 1 Cancer in Ontario An overview Cancer is a group of more
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 Menzies Centre For Population Health Research Editors: Dace Shugg, Terence Dwyer and Leigh Blizzard Publication
Tumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
Subject Cancers in Firefighters and Fire Investigators
If a firefighter or a fire investigator is diagnosed with a prescribed on or after January 1, 1960, and meets the employment duration and additional criteria for the prescribed, then the disease is presumed
National Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
TUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
A gene expression bar code for microarray data
A gene expression bar code for microarray data Michael J Zilliox & Rafael A Irizarry Supplementary figures and text: Supplementary Figure 1: Bar code heatmaps, dendrograms, and summaries. Supplementary
21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma,
21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma, Glioblastoma [Kindle Edition] By National Cancer Institute
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
Annual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers
EMBARGOED FOR RELEASE CONTACT: Friday, March 31, 2017 NCI Media Relations Branch: (301) 496-6641 or 10:00 am EDT ncipressofficers@mail.nih.gov NAACCR: (217) 698-0800 or bkohler@naaccr.org ACS Press Office:
Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia
Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health Racial and Ethnic Disparities in
Neoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
Supplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
Liver cancer and normal cell lines
The Essentials of Life Science Research Globally Deed Liver cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed HTB-79 Capan-1 pancreas: adenocarcinoma
Cancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
micrornas!as! Biomarkers! Landscape!
GENReports: Market & Tech Analysis micrornas!as! Biomarkers! Landscape! > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic Introduction and Scope! The,focus,of,this,GEN,Market,&,Tech,Analysis,Report,is,to,provide,
Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption
Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption X Dong, Y Ren, R Wilson, and K Zhang NAACCR 6-20-2017 Introduction
Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser
Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Melissa S. Cline 1*, Brian Craft 1, Teresa Swatloski 1, Mary Goldman 1, Singer Ma 1, David Haussler 1, Jingchun Zhu 1 1 Center for Biomolecular
Icd 10 code for lung cancer with mets to bone
Icd 10 code for lung cancer with mets to bone 1-10-2017 ICD-10 -CM Diagnosis Code. Cancer metastatic to bone ;. The majority of metastatic neoplasms to the bone are carcinomas. ICD - 10 -CM C79.51 is grouped.
CANCER Uncontrolled Cell Division
CANCER Uncontrolled Cell Division What is cancer? Why does it occur? Where does it occur? Benign vs. Malignant? Types of Cancer (3 main groups) There are over 200 different types of cancer 1) Carcinomas
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
Oncology Centre Research Unit TUMOR REGISTRY
1 Oncology Centre Research Unit TUMOR REGISTRY ANNUAL REPORT 2013 1 Annual Report Prepared by the Staff of the Tumor Registry Research Unit, Oncology Centre King Faisal Specialist Hospital and Research
Cancer in Ireland with estimates for
Cancer in Ireland 1994-2015 with estimates for 2015-2017: Annual Report of the National Cancer Registry 2017 Page ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised
Supplemental Data. Prolonged Rapamycin Treatment Inhibits mtorc2 Assembly and Akt/PKB. Supplemental Experimental Procedures
Supplemental Data Prolonged Rapamycin Treatment Inhibits mtorc2 Assembly and Akt/PKB Dos D. Sarbassov, Siraj M. Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P. Hsu, Alex F. Bagley, Andrew L. Markhard, and
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
Tissue Core Tissue Microarray Inventory List
size/mm Array description Tissue type # of cases AQUA 1 Pancreas AQUA 1 Pancreas 10 / 2012 1.0 Pancreas IDC, Panin, IPMN, normal & cysts various types Pancreas 21 51 Dr. Malafa / Dr. Centeno Exclusive
Cancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
Tumours in the donor: what is the risk?
Tumours in the donor: what is the risk? Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta@on CHU Liège, University of Liege, Belgium olivier.detry@transplanta@on.be Financial Disclosure Research